NewAmsterdam Pharma Company N.V.

NASDAQ•NAMS

CEO: Dr. Michael Harvey Davidson FACC, Facp., M.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-02-09

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

联系方式

Gooimeer 2-35, Naarden, 1411 DC, Netherlands

31-35-206-2971

www.newamsterdampharma.com

市值

$3.55B

市盈率 (TTM)

-17.3

24.5

股息率

52周最高

$42.21

52周最低

$17.63

52周范围

52%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基于 5 年期基本面

疲弱 • 2.2 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2021-2025

财务仪表盘

Q1 2026 数据

营业收入

$3.04M+0.00%

近4季度走势

每股收益

-$0.40+0.00%

近4季度走势

自由现金流

-$30.64M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Phase 3 Trials Met Endpoints Obicetrapib met primary LDL-C lowering endpoints in BROADWAY and BROOKLYN Phase 3 trials, showing strong efficacy.

Menarini Regulatory Submissions Complete MAAs submitted to EMA/UK/Switzerland for obicetrapib; decisions anticipated in second half of 2026.

Operating Loss Decreased Annual loss for the year narrowed by $37.8M to $203.8M, despite revenue falling 50.6% to $22.5M.

Cash Position Supports Operations Ending cash, equivalents, and restricted cash totaled $491.3M as of December 31, 2025, sufficient for near-term needs.

关注风险

Clinical Stage and Profitability Risk Company remains clinical-stage, incurred $203.8M loss in 2025, and anticipates continued significant losses indefinitely.

Substantial Financing Required Requires substantial additional capital to achieve goals; failure to secure funding could delay or terminate product development efforts.

Increased Cash Used Investing Cash used in investing activities rose sharply to $174.9M in 2025, contributing to a $280.4M decrease in total cash balance.

Dependence on Obicetrapib Success Future success entirely dependent on successful clinical development, regulatory approval, and commercialization of obicetrapib.

前瞻展望

Complete PREVAIL Cardiovascular Outcomes Continue executing PREVAIL CVOT to evaluate MACE benefit; earliest conclusion expected end of 2026 or later.

Await European Regulatory Decisions Anticipate Menarini receiving regulatory decisions on MAAs from European regulators in the second half of 2026.

Initiate Alzheimer's Disease Trial Expect to initiate a new clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease during 2026.

Pursue US Commercialization Strategy Current plan focuses on pursuing development and commercialization in the United States ourselves, considering additional partners.

同行对比

营业收入 (TTM)

ARWR

$622.01M

+9.4%

SLNO

$285.01M

+0.0%

LGND

$274.48M

+51.2%

毛利率 (最新季度)

ARWR

100.0%

+50.6pp

KYMR

100.0%

-2680.7pp

PTGX

99.3%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
ARWR	$10.50B	-35.3	-55.4%	60.5%
KYMR	$7.09B	-26.7	-25.0%	4.8%
PTGX	$7.06B	-62.3	-17.8%	1.4%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-45.8%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年8月5日

每股收益:-$0.48

营业收入:$1.79M

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据